CAMP4 Therapeutics Corporation Company Profile
NASDAQ: CAMPHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
CAMP4 Therapeutics at a glance
CAMP4 Therapeutics Corporation (NASDAQ: CAMP) is a Biotechnology company in the Healthcare sector headquartered in Cambridge, MA. CAMP4 Therapeutics is led by Mr. Joshua Mandel-Brehm and employs about 48 people. The company's shares have traded publicly since 2024.
At a market capitalization of $241.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001736730, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does CAMP4 Therapeutics do?
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- CAMP4 Therapeutics Corporation
- Ticker
- NASDAQ: CAMP
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Joshua Mandel-Brehm
- Employees
- 48
- Headquarters
- One Kendall Square, Cambridge, MA, United States
- Phone
- 617 651 8867
- Website
- camp4tx.com
- IPO year
- 2024
- Market cap
- $240.97M
- SEC CIK
- 0001736730
Companies similar to CAMP4 Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PYXSPyxis Oncology Inc. | 2.01 | -0.49% | $240.11M | vs CAMP |
| VOGXVogenx Inc | 16.16 | -1.40% | $240.06M | vs CAMP |
| LCTXLineage Cell Therapeutics Inc. | 0.9476 | +1.03% | $239.66M | vs CAMP |
| STROSutro Biopharma Inc. | 14.66 | +1.45% | $243.08M | vs CAMP |
| QTTBQ32 Bio Inc. | 7.99 | -1.48% | $237.86M | vs CAMP |
| SLGLSol-Gel Technologies Ltd. | 71.95 | -4.88% | $235.55M | vs CAMP |
| NAUTNautilus Biotechnology Inc. | 1.96 | +10.73% | $249.42M | vs CAMP |
| IMRXImmuneering Corporation Class A | 3.86 | +0.78% | $249.73M | vs CAMP |